Canadian CANNAINVESTOR Magazine Canada March / April 2019 | Page 106

I would tell them that this is very early days for one, again we are only just over 140 days from full legalization in Canada and the retail environment is still in a period where it’s trying to establish its place. We have taken a unique approach to our retail concept and again its early days, but we are really encouraged by the reaction from consumers thus far. As I previously mentioned, our Prairie Records stores are designed to be places where customers will feel a different vibe. Most stores to date are one of two things, either they are trying to be the Apple store of cannabis or they look like a headshop. Our stores, under the banner Prairie Records are designed as modern vinyl shops where the product information is displayed on LP album covers, connecting the product with types of music and evoking the instinctual tie between music and cannabis. So, if you are looking for a sleep aid, you may look under “lullabies”, if you are looking for something a little more upbeat, a “dance track” will lead you to the matching product. The response to the concept has been enthusiastic to say the least and we are excited about it. The bottom line is that the retail experience and the brand experience will be the differentiator for the retail business and we strongly believe Prairie Records will be a big hit. Telling an authentic brand story, while staying within the federal packaging and advertising restrictions and the provincial retail restrictions, is a very interesting challenge. We think we have nailed it and the early reaction from the consumer is that we have developed a successful recipe for success.

A recent Ipsos poll revealed that two thirds of Canadians would try a cannabis based medication if prescribed by a Doctor and if covered by benefits. Does Westleaf have any intentions on serving or having a presence in the medical stream? Regardless, do you foresee a DIN being assigned … perhaps as pharmaceutical companies work with LPs on developing qualifying trials and formulations?

106